SmartTarget technology and related assets have been acquired by Miami-based Intuitive Fusion LLC for inclusion in its Focalyx Fusion product which is delivered into clinical practice through its dedicated client SmartBlate LLC.

The UK trademark “SmartTarget” has been acquired by Ohio-based ViewRay Inc. (VRAY).


Target Accurately

  • Bespoke algorithms enforce realistic deformation of MR model
  • Mathematically best-fit image fusion
  • Live needle guidance mode enables precise positioning
  • 3D visualisation ensures max length tumour core targeting

Target Simply

  • Clinician-designed User Interface
  • Intuitive workflow
  • Fast & easy ultrasound contouring
  • Works with any ultrasound manufacturer
  • Radiologist-friendly MR contouring

Target Smarter

  • Transperineal approach reduces infection risk
  • Unique prostate MRI database underpins mathematical shape model
  • Machine learning techniques assure accurate deformation 
  • Core technology on method and modelling protected by worldwide patents

Evidence is mounting rapidly with regards to the patient benefit of a prostate cancer care pathway guided by MR imaging and targeted biopsy.  Clinicians at University College London Hospitals have been working over the past five years with researchers in UCL’s Centre for Medical Image Computing to develop an image fusion software for transperineal targeting of the prostate. The resulting CE-marked SmartTarget® device is specifically designed to be agnostic to the clinic’s MR and ultrasound equipment, intuitive for the user, fast to set up and slipping easily into existing clinical workflows with minimal disruption. Having also benefitted from funding by the UK’s Department of Health and the Wellcome Trust, we are pleased to offer a system that is affordable for both the public and private healthcare sectors.

Please contact us today to arrange a demonstration or speak to us further about the benefits and credentials of the SmartTarget® system.

Step 1

Planning: contoured MR image identifies areas of suspicious tissue.

Step 2

Modelling: our patented technology creates anatomically accurate deformable model of prostate and tumour(s).

Step 3

Fusion: model mapped accurately to dynamic ultrasound image giving augmented visibility of tumour location enabling  precision targeting.

“The SmartTarget image fusion software works extremely well for me. It is accurate, swift and very easy to use, for both transperineal local and sedation biopsies. Additionally, the same software very nicely guides focal therapy – we have tried it with a number of ablative modalities.”

Mr Hashim Ahmed, Honorary Consultant Urological Surgeon, UCL Hospitals

News and Events

SmartTarget Ltd announces sale of technology to Miami-based Intuitive Fusion LLC.

SmartTarget Ltd announces sale of technology to Miami-based Intuitive Fusion LLC.

London, (24 January 2020) SmartTarget Ltd, a spinout company of UCL which successfully brought to market image fusion technology allowing...

MRI Masterclass for the Diagnosis and Management of Prostate Cancer

MRI Masterclass for the Diagnosis and Management of Prostate Cancer

SmartTarget once again supported UCL’s “MRI Masterclass for the Diagnosis and Management of Prostate Cancer” at the UCLH Education Center...

BAUS 2019

SmartTarget is back at BAUS 2019 for the biggest urology event on the calendar. If you are attending, stop by...

Cambridge Prostate mpMRI & Biopsy Course

Cambridge Prostate mpMRI & Biopsy Course

photo courtesy of Page Photography SmartTarget presented its MRI TRUS fusion technology to the Cambridge Prostate mpMRI & Biopsy Course...

Healthcare in Europe

Healthcare in Europe

Healthcare In Europe has published an overview of the SmartTarget biopsy study performed at UCLH. The article included commentary by...

American Urological Association 2019

American Urological Association 2019

SmartTarget attended the American Urological Association conference in Chicago, USA this past week to meet with a range of companies...

1 2 3

Book a demo with our team now